Tone mix
Week by week 52 weeks
Share of Mannkind Corporation's 167 headlines over the last 52 weeks by the model's call, and the same mix week by week.
Biggest swings in the last year
The weeks whose tone moved furthest from the 8-week average, with the story most outlets carried that week.
- Week of Jul 13, 2026 · tone -56Y Intercept Hong Kong Ltd Cuts Stock Holdings in MannKind Corporation $MNKD-125
- Week of Apr 13, 2026 · tone +99Truist Securities Touts MannKind Corporation (MNKD) Prospects on Tyvaso Franchise Development+89
- Week of Dec 29, 2025 · tone +100MannKind Corporation (MNKD) Secures FDA Approval for FUROSCIX Pediatric Use, Expanding Reach In Heart, Kidney Disease Care+85
- Week of Dec 1, 2025 · tone +99MannKind's SubQ Furosemide Autoinjector Accepted for FDA Review+85
- Week of Aug 31, 2026 · tone +100MannKind Corporation (NASDAQ:MNKD) Receives Consensus Recommendation of "Moderate Buy" from Analysts+79
- Week of Sep 15, 2025 · tone 0MannKind : Acquisition of scPharmaceuticals Presentation (a83ff3)-78
Daily headline tone, last 90 sessions
Hover a session for its totals; click to pin.
Each point is the average score of the headlines about Mannkind Corporation in one trading session, with the 8-session average drawn through it. Sessions with no headline about the company have no point.
Tone by period
Show the table · 3 rows, 3 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Last 7 sessions | 4 | +49 |
| Last 30 sessions | 10 | +20 |
| Last 90 sessions | 42 | +20 |
No matching rows. Clear the filter to see all records.
Every headline in the period counts equally.
Headlines on Friday, October 23, 2026
1 headline, average tone +98: 1 positive, 0 neutral and 0 negative. Showing all 1.
- www.themarketsdaily.com · 1 outletMannKind Advances Inhaled IPF Drug to Global Phase 2, Eyes FUROSCIX GrowthPositive
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| MannKind Advances Inhaled IPF Drug to Global Phase 2, Eyes FUROSCIX Growth | www.themarketsdaily.com | 1 | Positive |
No matching rows. Clear the filter to see all records.
Headlines on Thursday, October 22, 2026
2 headlines, average tone 0: 0 positive, 2 neutral and 0 negative. Showing all 2.
- www.tickerreport.com · 1 outletMannKind (NASDAQ:MNKD) and Monte Rosa Therapeutics (NASDAQ:GLUE) Head-To-Head AnalysisNeutral
- www.dailypolitical.com · 1 outletFinancial Analysis: MannKind (NASDAQ:MNKD) & Iovance Biotherapeutics (NASDAQ:IOVA)Neutral
Show the table · 2 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| MannKind (NASDAQ:MNKD) and Monte Rosa Therapeutics (NASDAQ:GLUE) Head-To-Head Analysis | www.tickerreport.com | 1 | Neutral |
| Financial Analysis: MannKind (NASDAQ:MNKD) & Iovance Biotherapeutics (NASDAQ:IOVA) | www.dailypolitical.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Wednesday, October 21, 2026
1 headline, average tone +98: 1 positive, 0 neutral and 0 negative. Showing all 1.
- www.tickerreport.com · 1 outletMannKind Advances Inhaled IPF Drug to Global Phase 2, Eyes FUROSCIX GrowthPositive
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| MannKind Advances Inhaled IPF Drug to Global Phase 2, Eyes FUROSCIX Growth | www.tickerreport.com | 1 | Positive |
No matching rows. Clear the filter to see all records.
Headlines on Friday, October 16, 2026
1 headline, average tone 0: 0 positive, 1 neutral and 0 negative. Showing all 1.
- www.tickerreport.com · 1 outletComparing MannKind (NASDAQ:MNKD) & Iovance Biotherapeutics (NASDAQ:IOVA)Neutral
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Comparing MannKind (NASDAQ:MNKD) & Iovance Biotherapeutics (NASDAQ:IOVA) | www.tickerreport.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Thursday, October 15, 2026
2 headlines, average tone 0: 0 positive, 2 neutral and 0 negative. Showing all 2.
- www.dailypolitical.com · 1 outletMonte Rosa Therapeutics (NASDAQ:GLUE) vs. MannKind (NASDAQ:MNKD) Critical SurveyNeutral
- www.manilatimes.net · 1 outletMannKind to Participate in the Chardan Healthcare ConferenceNeutral
Show the table · 2 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Monte Rosa Therapeutics (NASDAQ:GLUE) vs. MannKind (NASDAQ:MNKD) Critical Survey | www.dailypolitical.com | 1 | Neutral |
| MannKind to Participate in the Chardan Healthcare Conference | www.manilatimes.net | 1 | Neutral |
No matching rows. Clear the filter to see all records.
How the score works
A headline's tone is not a forecast of the share price. Read the headlines themselves before acting on an average.
Which headlines count
Headlines come from the GDELT global news feed from 2019-09-23 on. A headline counts only when a model judges it to be about Mannkind Corporation, not a passing mention.
How each headline is scored
The model calls each headline positive, neutral or negative news for the company. A period's tone is the share of positive minus negative headlines, from -100 (all negative) to +100 (all positive).
When a headline counts
Headlines published by 9:15 a.m. New York time belong to that day's session. Later and weekend headlines move to the next trading session.
Repeated stories
When several outlets carry the same headline, it counts once per session.